menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Milestone Pharmaceuticals to Present Etripamil Data at ACC

    GLOBENEWSWIRE

    Milestone Pharma Notice of Allowance on New Patent for Etripamil

    GLOBENEWSWIRE

    Milestone Pharmaceuticals To Host Investor Event On Feb 25 In NYC

    GLOBENEWSWIRE

    Milestone Pharmaceuticals to Host Investor KOL Event

    GLOBENEWSWIRE

    Milestone Partner Ji Xing Reports Positive Ph 3 Results For Etripamil In PSVT

    GLOBENEWSWIRE

    Milestone Partner Ji Xing Pharma, Positive Result of Ph 3 Study in PSVT in China

    GLOBENEWSWIRE

    Milestone Pharmaceuticals Adds Joseph Papa To Board

    GLOBENEWSWIRE

    Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

    GLOBENEWSWIRE

    Milestone Pharma Reports Q1 2024 Results, Regulatory And Corporate Update

    GLOBENEWSWIRE

    Milestone: Etripamil Data At Heart Rhythm, Stanford, ISPOR 2024

    GLOBENEWSWIRE

    Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative CNS

    GLOBENEWSWIRE

    Milestone Announces Etripamil Data at The American College of Cardiology Meeting

    GLOBENEWSWIRE

    Milestone to Present Data on Etripamil at the Association Annual Conferences

    GLOBENEWSWIRE

    Milestone Announces Resubmission of NDA for Etripamil for Treatment in PST

    GLOBENEWSWIRE

    Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil

    GLOBENEWSWIRE

    Milestone Pharma Receives Refusal to File Letter from FDA for NDA for Etripamil

    GLOBENEWSWIRE

    Milestone Pharma Presents Positive Results from Phase 2 Study of Etripamil

    PR NEWSWIRE

    Milestone Pharmaceuticals to Host Investor and Analyst Webcast

    PR NEWSWIRE

    Milestone Announces Submission of NDA to the U.S. FDA for Etripamil

    PR NEWSWIRE

    Milestone nnounces Publication of Results from Ph3 RAPID Trial of Etripamil

    PR NEWSWIRE

    Milestone Pharma Progresses Clinical and Regulatory Activities for Etripamil

    PR NEWSWIRE

    Selagine Enters into a Collaborative Agreement with Grifols

    PR NEWSWIRE

    Milestone Pharma to Present Data from PIII NODE-302 Study of Etripamil

    PRNEWSWIRE

    Milestone Pharma to Host Virtual Key Opinion Leader Event on Etripamil

    PRNEWSWIRE

    Milestone Announces First Patient Enrolled in RAPID, a Pivotal Ph 3 Etripamil

    PRESS RELEASE

    Milestone Announces Regulatory Guidance &Updated Clinical DEV Plan for Etripamil

    PRNEWSWIRE

    Milestone Announces Topline Results from First-of-its-kind Phase 3 NODE-301

    PR NEWSWIRE

    Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

    PR NEWSWIRE

    Four biotechs haul in $303M+ from a fresh burst of IPOs

    ENDPTS

    Milestone Pharmaceuticals Announces $80 Million Private Financing

    PR NEWSWIRE

    Milestone Pharma grabs an $80M round

    ENDPTS

    Milestone Pharma preps a leap into Ph3 cardio study $55M round backed by Novo

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.